GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Optipharm Co Ltd (XKRX:153710) » Definitions » Enterprise Value

Optipharm Co (XKRX:153710) Enterprise Value : ₩73,648 Mil (As of May. 13, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Optipharm Co Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Optipharm Co's Enterprise Value is ₩73,648 Mil. Optipharm Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-1,812 Mil. Therefore, Optipharm Co's EV-to-EBIT ratio for today is -40.64.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Optipharm Co's Enterprise Value is ₩73,648 Mil. Optipharm Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-198 Mil. Therefore, Optipharm Co's EV-to-EBITDA ratio for today is -371.85.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Optipharm Co's Enterprise Value is ₩73,648 Mil. Optipharm Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was ₩19,636 Mil. Therefore, Optipharm Co's EV-to-Revenue ratio for today is 3.75.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Optipharm Co's Enterprise Value is ₩73,648 Mil. Optipharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-2,332 Mil. Therefore, Optipharm Co's EV-to-FCF ratio for today is -31.59.


Optipharm Co Enterprise Value Historical Data

The historical data trend for Optipharm Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optipharm Co Enterprise Value Chart

Optipharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 202,316.95 121,156.41 93,939.74 97,525.46 64,919.48

Optipharm Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97,525.46 99,195.52 88,870.03 75,019.34 64,919.48

Competitive Comparison of Optipharm Co's Enterprise Value

For the Diagnostics & Research subindustry, Optipharm Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Optipharm Co's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Optipharm Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Optipharm Co's Enterprise Value falls into.


;
;

Optipharm Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Optipharm Co's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Optipharm Co's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Optipharm Co  (XKRX:153710) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Optipharm Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=73647.912/-1812.236
=-40.64

Optipharm Co's current Enterprise Value is ₩73,648 Mil.
Optipharm Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1,812 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Optipharm Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=73647.912/-198.059
=-371.85

Optipharm Co's current Enterprise Value is ₩73,648 Mil.
Optipharm Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-198 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Optipharm Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=73647.912/19636.228
=3.75

Optipharm Co's current Enterprise Value is ₩73,648 Mil.
Optipharm Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩19,636 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Optipharm Co's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=73647.912/-2331.655
=-31.59

Optipharm Co's current Enterprise Value is ₩73,648 Mil.
Optipharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-2,332 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Optipharm Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of Optipharm Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Optipharm Co Business Description

Traded in Other Exchanges
N/A
Address
6, 63 Osong, Hwaseong-eup, Heungduk-gu, Chungcheongbuk-do, Cheongju, KOR
Optipharm Co Ltd is engaged in developing cell therapy products through animal stem cells, developing high value-added protein drugs using bio-reactors, selecting antibiotic/antiviral components and developing products. Its diagnosis division includes human diagnosis and animal diagnosis that focuses on the development of molecular diagnostics for a variety of diseases.

Optipharm Co Headlines

No Headlines